Hunan Jiudian Pharmaceutical Co Ltd (SHE:300705) — Market Cap & Net Worth
Market Cap & Net Worth: Hunan Jiudian Pharmaceutical Co Ltd (300705)
Hunan Jiudian Pharmaceutical Co Ltd (SHE:300705) has a market capitalization of $940.58 Million (CN¥6.43 Billion) as of May 3, 2026. Listed on the SHE stock exchange, this China-based company holds position #9365 globally and #2556 in its home market, demonstrating a -6.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hunan Jiudian Pharmaceutical Co Ltd's stock price CN¥12.85 by its total outstanding shares 500212488 (500.21 Million). Analyse cash flow conversion of Hunan Jiudian Pharmaceutical Co Ltd to see how efficiently the company converts income to cash.
Hunan Jiudian Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Hunan Jiudian Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $465.04 Million to $940.58 Million (15.92% CAGR).
Hunan Jiudian Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hunan Jiudian Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.45x
Hunan Jiudian Pharmaceutical Co Ltd's market cap is 0.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.56x
Hunan Jiudian Pharmaceutical Co Ltd's market cap is 2.56 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $465.04 Million | $534.52 Million | $68.57 Million | 0.87x | 6.78x |
| 2018 | $418.26 Million | $801.38 Million | $71.99 Million | 0.52x | 5.81x |
| 2019 | $439.94 Million | $924.06 Million | $55.07 Million | 0.48x | 7.99x |
| 2020 | $962.52 Million | $978.16 Million | $82.26 Million | 0.98x | 11.70x |
| 2021 | $1.26 Billion | $1.63 Billion | $204.25 Million | 0.78x | 6.19x |
| 2022 | $1.24 Billion | $2.33 Billion | $269.70 Million | 0.53x | 4.61x |
| 2023 | $1.72 Billion | $2.69 Billion | $368.26 Million | 0.64x | 4.66x |
| 2024 | $1.31 Billion | $2.93 Billion | $512.38 Million | 0.45x | 2.56x |
Competitor Companies of 300705 by Market Capitalization
Companies near Hunan Jiudian Pharmaceutical Co Ltd in the global market cap rankings as of May 3, 2026.
Key companies related to Hunan Jiudian Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Hunan Jiudian Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Hunan Jiudian Pharmaceutical Co Ltd's market cap moved from $465.04 Million to $ 940.58 Million, with a yearly change of 15.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥940.58 Million | -14.22% |
| 2025 | CN¥1.10 Billion | -16.55% |
| 2024 | CN¥1.31 Billion | -23.41% |
| 2023 | CN¥1.72 Billion | +38.04% |
| 2022 | CN¥1.24 Billion | -1.67% |
| 2021 | CN¥1.26 Billion | +31.30% |
| 2020 | CN¥962.52 Million | +118.78% |
| 2019 | CN¥439.94 Million | +5.18% |
| 2018 | CN¥418.26 Million | -10.06% |
| 2017 | CN¥465.04 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Hunan Jiudian Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $940.58 Million USD |
| MoneyControl | $940.58 Million USD |
| MarketWatch | $940.58 Million USD |
| marketcap.company | $940.58 Million USD |
| Reuters | $940.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Pat… Read more